Insights on AI, medical research, and the future of scientific discovery.
Reading papers is not the same as extracting usable data from them. Most literature reviews produce summaries when they should produce structured datasets.
Read more →
Most clinical trial failures are not failures of execution. They are failures of design that were locked in before the first patient was enrolled.
Read more →
Most teams use AI to find papers faster. That is the least interesting thing it can do. Here is what changes when you treat it as a research infrastructure.
Read more →
Every researcher learns about bias in methods training. Most learn a list of names. What is harder to teach is how to recognise them in your own work before peer review does it for you.
Read more →
A rapid review done poorly is worse than no review at all. It gives false confidence in conclusions drawn from incomplete evidence. Here is how to do it properly.
Read more →
Real-world evidence is being used to support regulatory decisions in ways that would have been unthinkable a decade ago. That is either exciting or alarming, depending on how well you understand its limits.
Read more →
Grant reviewers read hundreds of applications. The ones that land are not the most ambitious ones. They are the ones that answer the right question in the right way.
Read more →
The replication crisis is not really a crisis of fraud. It is a crisis of incomplete evidence at the design stage, and that is a problem we can actually fix.
Read more →
We have had the same conversation more times than we can count. A researcher tried a tool, stopped using it within weeks, and can explain exactly why. The explanations are remarkably consistent.
Read more →
Accuracy is necessary. It is not sufficient. The most dangerous AI systems in medicine are not the ones that are wrong, they are the ones that are wrong with confidence.
Read more →
The distance between a stack of relevant papers and a finished protocol is longer than it looks. This is about what happens in that space.
Read more →
The AI drug discovery revolution arrived later than expected and works differently than advertised. The tools that are actually delivering value are less dramatic and more useful.
Read more →Join leading pharmaceutical companies, hospitals, biotech labs, CROs, and research centers using NousLab to accelerate medical breakthroughs.
Schedule a DemoTalk to our team to learn about licensing options for your organization